Financial Performance - As of Q3 2024, the company achieved a revenue of 190.94 million yuan, representing a year-on-year growth of 30.98% [3] - The net profit attributable to shareholders was 52.80 million yuan, with a significant increase of 107.68% compared to the same period last year [3] - The net profit after deducting non-recurring gains and losses reached 46.08 million yuan, marking a growth of 108.37% year-on-year [3] Product Development and Market Strategy - The company focuses on the neurosurgery field, offering a range of key implantable medical devices, including artificial dura mater patches and absorbable regenerated cellulose products [4] - Sales revenue from absorbable regenerated cellulose and dura mater medical glue exceeded 20 million yuan, showing an increase of nearly 90% compared to the previous year [3] - The company is actively promoting new products and expanding their applications in various surgical fields [3][4] Inventory and Sales Team - The increase in inventory levels compared to the beginning of the year is attributed to normal business needs [4] - The marketing team has seen an increase in personnel compared to the previous year, with plans for further growth to meet the demands of a diversified product line [5]
迈普医学(301033) - 2024年10月29日投资者关系活动记录表